Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials
Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.
bovnews21h
What’s Fueling Exelixis Inc (EXEL) Stock’s 25.88% Gain Above Its 200-Day SMA?
On Wednesday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $29.35 which represents a slight increase of $0.85 or 2.98% from the prior close of $28.5. The stock opened at $28.7 and ...
C4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific ...